Drug Approval | May 28, 2026
Lupin’s Ankleshwar facility receives EIR from U.S. FDA
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The development comes as stroke remains one of the world’s biggest health threats
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
